Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Adverse Event Active Surveillance Extends Into Emergency Rooms

Executive Summary

FDA has expanded its adverse drug event active surveillance program into 65 emergency rooms nationwide

You may also be interested in...



FDA/CDC Active Surveillance System Could Assess Effect Of Safety Measures

A collaborative national electronic active surveillance system co-sponsored by FDA and the Centers for Disease Control & Prevention could be used to examine the impact of safety measures on the number of adverse drug events, CDC medical officer Dan Budnitz said July 7

FDA/CDC Active Surveillance System Could Assess Effect Of Safety Measures

A collaborative national electronic active surveillance system co-sponsored by FDA and the Centers for Disease Control & Prevention could be used to examine the impact of safety measures on the number of adverse drug events, CDC medical officer Dan Budnitz said July 7

FDA Drug Safety Oversight Could Be “Transformed” By Medicare Data

FDA should develop an active surveillance system using prescription drug claims data from the Medicare population to supplement its existing drug safety system, members of the agency's Drug Safety & Risk Management Advisory Committee said May 18 and 19

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel